Akshjot Puri

Breast medical oncologist, breast cancer research, #HoustonMethodistCancerCenter Views are my own.

[Akshjot Puri @AkshjotP]

What a pleasure to present next to @mfrimawi @hmcarthur @CairoMichelina ,Dr Senthil Damodaran, moderated by @JAMouabbi at this Moment in Medicine Program by @CHMediaHub. A night of thought provoking discussions, learning different perspectives in today’s breast cancer landscape

[Akshjot Puri @AkshjotP]

RT @CHMediaHub: Drs. @mazo_md , Canola , @AkshjotP , and Mascol talk about how aapivasertib is transforming the HR+/HER2- metastatic breast…

[Akshjot Puri @AkshjotP]

Very insightful discussions tonight about antibody drug conjugates and the changing world of breast cancer. Thank you to my co moderator Dr Senthil Damodaran and @DeceraClinEdu for such a fun night full of learning. Ending with a quick cameo by @JAMouabbi

[Akshjot Puri @AkshjotP]

Thank you @HMethodistMD @Rice_Biz @MdSchaal @matei_dem for such a unique opportunity. I have learnt how to think differently, developed new perspectives and strengthened my leadership skills.

[Paolo Tarantino @PTarantinoMD]

ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. https://t.co/9DMLLo8lOn

[Akshjot Puri @AkshjotP]

The Methodist breast oncology team takes on #SABCS24 @JennyCChang1 Polly Niravath @DrKaiSun

[Akshjot Puri @AkshjotP]

Checkout our poster in advanced pretreated metaplastic breast cancer now treated with combination of pan NOS inhibitor, alpelisib and nab-paclitaxel, ORR increased from historic 10-15% to 44.4% and an impressive CBR of 77%!! Presented by Polly Niravath @JennyCChang1 #sabcs2024

[Akshjot Puri @AkshjotP]

Multi factor analysis from our trial with durvalumab, trastuzumab and pertuzumab, presented by our breast division chair Polly Niravath @JennyCChang1 at #SABCS2024. Path CR 50% with a chemo free approach in HER2 enriched ER neg HER2 positive early breast cancer.

[Elisa Agostinetto @ElisaAgostinett]

Dose-dense vs. 3-weekly AC during neoadjuvant chemoimmunotherapy for TNBC
Interesting real-world data addressing an important question for clinical practice
No statistical significant difference observed; numerical ⬆️pCR for ddAC in stage 3️⃣
@OncoAlert
https://t.co/vyYx2tExOQ

[Nancy Lin, MD @nlinmd]

EAZ171: Prospective study of adj taxane in Black women

⬆️G2 or higher neuropathy with weekly paclitaxel vs Q3W docetaxel - 40% vs 24%

⬆️dose reductn for neuropathy w/P vs D (28% vs 9%)

Highlights importance of diverse trial accrual to optimize tx

https://t.co/RBBuCJrd9b

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Five trials of AC/T chemo +/- carboplatin for stage 2/3 TNBC with DFS/EFS endpoints.

CALGB 40603 (❎)
BrighTNess (✅)
GeparSixto (✅)
Gupta S, (SABCS) 2022, GS5-01 (✅)
BR 15-1 PEARLY ASCO 2024 (✅)
Unofficial meta-analyis: looks like carboplatin reduces recurrence in TNBC.

[Nancy Lin, MD @nlinmd]

TBCRC 049: Tucatinib, trastuzumab, capecitabine for HER2+ LMD
-The first prospective LMD trial to show all of the following:
-therapeutic drug levels in CSF
-intracranial response
-improvement in symptoms and QoL
-extended OS compared to historical controls

[Paolo Tarantino @PTarantinoMD]

Great recap of the data with carboplatin for TNBC by @JavierCortesMD #ASCO24

[Jenny C. Chang @JennyCChang1]

“Premenopausal” women w low antimullerian hormone <55 yo and RS<25 had no benefit from adjuvant chemo in Rxponder. Great work to decrease toxicity #ASCO24 #bcsm

[Jenny C. Chang @JennyCChang1]

@asco2024 @BCSMChat A Brave trial presented by Conte et al - interesting benefit with avelumab in high risk adjuvant and in those w residual disease post NACT in TNBC #tnbc @AkshjotP

[Jenny C. Chang @JennyCChang1]

@asco2024 @BCSMChat Results from TBCRC 048 - Parpi has efficacy in sBRCA mutations and high efficacy in gPALB2-great to see results are holding out. Great work -sets the treatment for these patients @AkshjotP #pollyniravath @TheTBCRC

[Jenny C. Chang @JennyCChang1]

@asco2024 @OncoAlert Destiny breast 06. Tdxd in HER2 low and ultra Low - PFS HR 0.62 in HER low and 0.78 in ultra low, expected ILD toxicity✅, confirming Daisy results. How low is low? @HMethodistMD @AkshjotP

[Elisa Agostinetto @ElisaAgostinett]

Can Mammaprint inform specific CT regimen planning (with or without anthracyclines) for pts who qualify for CT?
At #ASCO24 an analyis of the FLEX trial shows that Mammaprint index could identify patients with ⬆️ benefit from anthracyclines
@OncoAlert

[Jenny C. Chang @JennyCChang1]

#ASCO24 @BCSMChat @OncoAlert another PIK3Ca inhibitor - in combination palbo/fulvestrant - improvement in PFS, 2nd PFS, delays chemo. Toxicity of mucositis, hyperglycemia, diarrhea, rash. Low discontinuation @AkshjotP

[Jenny C. Chang @JennyCChang1]

#ASCO24 #bcsm @HMethodistMD @AkshjotP @EfstathiouEleni @MaenAbdelrahim PostMonarch shows improved PFS in continuing CDKi - this phase 3 is practice changing